RESLIZUMAB
UNII 35A26E427H

Substance Identification & Data

This profile provides standardized clinical and technical data for Reslizumab, uniquely identified by the FDA Unique Ingredient Identifier (UNII) 35A26E427H.

Technical mappings include the Chemical Abstracts Service (CAS) Registry Number 241473-69-8 and the RxNorm Concept ID (RxCUI) 1746889. Explore the sections below for detailed nomenclature and a complete directory of NDC-listed products containing this ingredient.

FDA UNII Code

35A26E427H

CAS Registry Number

241473-69-8

RxNorm Concept ID

1746889

Detailed Substance Profile

Preferred Name

RESLIZUMAB

Official standardized name for this substance within the FDA UNII nomenclature system.

Molecular Formula

35A26E427H

The specific atomic composition represented as a molecular structure string.

NCI Thesaurus

C152197

National Cancer Institute reference terminology for clinical and research data.

INN ID

8106

Sequential identifier assigned via the WHO International Nonproprietary Name program.

USAN ID

LL-65

Identifier assigned by the United States Adopted Names Council.

Substance Type

protein

ISO 11238 classification category (e.g., Chemical, Polymer, Protein).

Synonyms and Nomenclature

This section provides a complete list of nomenclature and identifier mappings for Reslizumab. Identifiers are organized into official regulatory terms, commercial trade names, and technical systematic synonyms used to ensure accurate identification across clinical pharmaceutical databases, regulatory filings, and electronic health records.

FDA Official Name

RESLIZUMAB

Common Names & Synonyms

IMMUNOGLOBULIN G4, ANTI-(HUMAN INTERLEUKIN 5) (HUMAN-RAT MONOCLONAL SCH 55700 .GAMMA.4-CHAIN), DISULFIDE WITH HUMAN-RAT MONOCLONAL SCH 55700 LIGHT CHAIN, DIMER

MAB HUMAN (IGG4) ANTI P05113 (IL5_HUMAN) (SCH55700)

RESLIZUMAB [INN]

RESLIZUMAB [MI]

RESLIZUMAB [PURPLE BOOK CDER]

RESLIZUMAB [USAN]

RESLIZUMAB [WHO-DD]